

Appendix: Components of Final Scoping Document

1. Scope, Rationale & Background

1.1 Rationale and Scope of Guideline

- Scope of current proposed guideline, including information on previous Task Force guidelines if applicable
- Why is there a need for a guideline? (e.g., to address variation in screening practices across Canada, poor evidence-based guidance, awareness of new evidence, new interventions)
- Summary of what is and is not included in scope and why

1.2 Background

- Overview of the disease/condition of interest, including natural course of disease (without intervention; in terms of specific outcomes [e.g., x leads to Y in 5 of 100 people]), some logic amongst the chain of outcomes if some are intermediary to others, and any other factors from the literature or clinical/content experts to consider
- Basic Canadian statistics on burden, how many people are affected, incidence/prevalence, trends over time, costs of disease
- Risk factors and populations that are at higher risk, with indication of magnitude as possible (e.g., risk ratios)

2. Intervention

- Rationale for screening or preventive intervention and how early diagnosis will improve outcomes (main goals with intervention)
- Description of intervention of interest, components, current clinical practice
- Preventive practices in Canada and relevant global jurisdictions – discuss differing scope and recommendations
- Description of the available screening tests or preventive measures
- Primary target(s) of intervention, potential benefits and harms
- How accurate are the tests? What influences the quality of the test results? (rigour depends on whether or not there is a KQ on this)
- What are the differences in screening strategies that may influence outcomes?
- Patient values and preferences in relation to intervention and potential outcomes
- Equity and other considerations (e.g., treatment effectiveness, different competing outcomes/risks [advantages of treatment vs. serious drug reactions], baseline prevalence, differences in access/acceptability of intervention) in relation to specific populations

2.1 Follow-up/Management

- What are the management strategies?
- What is the effectiveness of management strategies? (amount of detail depends on whether or not there is a KQ on this)
- Follow up treatment or other interventions

3. Recent Evidence-based National Guidance from Canada and Other Countries


- Comparison of guidelines (recommendations, implementation considerations, and what impacted these [e.g., quality of evidence, uncertainties])
- Other relevant guidelines (e.g., those not underpinned by systematic reviews if applicable)
 - Recommendations by key Canadian bodies or funded by provinces, even if not underpinned by systematic review, should be included to help understand the status quo.

4. Summary of Relevant Systematic Reviews and Available Evidence

- Analysis of key differences between reviews (e.g., describe reasons for different outcomes)
 - Begin with systematic reviews that underpin guidelines in section 3
- Similarities and differences in scope, main questions and results
- High level narrative summary of table contents
- Summary of estimated amount and quality of literature, any new evidence that we are aware of, and any anticipated gaps
- Analysis of reviews that could be adapted or updated to inform guideline, and implications of doing this (e.g., where there may be a paucity of evidence, issues/variation with defining population or interventions)

5. Analytical Framework

Example: Screening to prevent fragility fractures among adults ≥ 40 years in primary care



6. Draft Key Questions and PICOTS (note: repeat sections for each KQ as needed)

6.1 KQ1 Description

- Key question written out in full (e.g., What are the benefits and harms of screening to prevent fragility fractures and related morbidity and mortality in primary care for adults ≥40 years?)

6.2 Eligibility Criteria

- **Population including specific populations:** Rationale (with references) for exclusions and inclusions
- **Interventions and comparators:** Rationale (with references) for exclusions and inclusions, including timing and duration
- **Outcomes:** Summary of rating process. Rationale for chosen outcomes (with references), including any timepoint considerations
 - Critical outcomes
 - Important outcomes
- **Timing:** Rationale for timing of outcome assessment (e.g., duration of follow-up if applied)
- **Setting:** Define
- **Study publication date:** Rationale for publication date (e.g., introduction of intervention, change in practices)

6.3 Table: KQ1 PICOTS

Table: PICOTS Inclusion and Exclusion Criteria for KQ1

	Inclusion	Exclusion
Population		
Intervention		
Comparator		
Outcome		
Timing		
Setting		
Study publication date		
Study design		
Language		